Tsung-Che Wu/X
Mar 12, 2025, 14:11
Tsung-Che Wu: Veritac-2 – Vepdegestrant vs fulvestrant in 2L breast cancer
Tsung-Che Wu, Medical oncologist at NTUH in Taiwan, shared a post on X:
“Veritac-2: Vepdegestrant (PROTAC ER degrader) vs fulvestrant in 2L breast cancer.
positive for one of the primary endpoint: PFS in ESR1mt but not in ITT
– Milestone for drug development: the first positive phase 3 study of PROTAC for solid tumor,
– ESR1mt is a crucial marker for ER depndency at 2L and beyond,
– Interesting to compare the data and biomarkers vs trials of oral SERD.”
VERITAC-2 Trial Update: Vepdegestrant Meets Primary Endpoint in ESR1-Mutant Breast Cancer
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Mar 12, 2025, 14:11
Mar 12, 2025, 13:56
Mar 12, 2025, 13:49
Mar 12, 2025, 13:45
Mar 12, 2025, 13:37
Mar 12, 2025, 13:30
Mar 12, 2025, 13:13
Mar 12, 2025, 13:13